PRESS RELEASES 2016

Dec 09
Sep 19
Nov 16

Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules

New York and Paris, November 16, 2016 Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets... read more →
May 19
Apr 20
Apr 18

Enterome in-licenses novel compounds from Vertex Pharmaceuticals to treat microbiome-related inflammatory bowel diseases

Paris, France and Boston, MA – April 18 2016 ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, has signed an exclusive worldwide license agreement with Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) to research, develop and commercialize novel small molecule FimH antagonists for... read more →
Apr 13

Enterome to participate at the FBR Healthcare Series Conference and the Guggenheim Securities Microbiome Day in New York

Paris, France and Boston, MA – April 13, 2016 ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announces that Pierre Bélichard, its Chief Executive Officer, will participate at the following conferences: FBR Healthcare Series: New Prescriptions: Innovation in the Treatment of... read more →
Jan 07

Enterome announces collaboration with Johnson & Johnson Innovation focused on the discovery of novel targets and therapeutics for Crohn’s disease

Paris, France and Boston, MA, USA – January 7, 2016 Enterome Bioscience SA announces that it has entered into a collaborative research agreement with Janssen Biotech, Inc. (Janssen Biotech), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the French National Institute for Agriculture Research (INRA). Read the... read more →
Jan 06

Takeda and Enterome enter strategic drug discovery collaboration focused on Microbiome Targets Across Multiple Gastrointestinal Disorders

Osaka, Japan, Paris, France and Boston, MA, USA — January 6, 2016 Takeda Pharmaceutical Company Ltd. and Enterome Bioscience SA today announced they have entered into a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders,... read more →